Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

OLMA | Olema Pharmaceuticals Inc

IndexRUT P/E- EPS (ttm)-2.41 Insider Own11.49% Shs Outstand40.29M Perf Week-11.24%
Market Cap473.46M Forward P/E- EPS next Y-2.23 Insider Trans41.82% Shs Float36.60M Perf Month-9.70%
Income-97.28M PEG- EPS next Q-0.49 Inst Own96.97% Short Float / Ratio4.81% / 6.20 Perf Quarter26.80%
Sales0.00M P/S- EPS this Y16.40% Inst Trans-1.79% Short Interest1.76M Perf Half Y253.40%
Book/sh3.93 P/B2.91 EPS next Y-1.62% ROA-45.43% Target Price21.57 Perf Year293.47%
Cash/sh4.05 P/C2.83 EPS next 5Y- ROE-48.90% 52W Range2.19 - 13.50 Perf YTD367.35%
Dividend- P/FCF- EPS past 5Y-158.58% ROI-59.76% 52W High-15.19% Beta2.45
Dividend %- Quick Ratio11.56 Sales past 5Y0.00% Gross Margin- 52W Low422.83% ATR0.87
Employees86 Current Ratio11.56 Sales Q/Q- Oper. Margin0.00% RSI (14)47.71 Volatility8.09% 7.30%
OptionableYes Debt/Eq0.01 EPS Q/Q40.04% Profit Margin- Rel Volume0.88 Prev Close11.25
ShortableYes LT Debt/Eq0.01 EarningsAug 08 AMC Payout- Avg Volume284.07K Price11.45
Recom1.12 SMA20-6.51% SMA507.50% SMA20073.59% Volume249,424 Change1.78%
Date Action Analyst Rating Change Price Target Change
Jul-21-23Initiated Oppenheimer Outperform $21
May-05-23Initiated CapitalOne Overweight $16
Feb-22-23Initiated Credit Suisse Outperform $12
Jul-06-22Resumed Canaccord Genuity Buy $16
Jun-09-22Upgrade H.C. Wainwright Neutral → Buy $12
Feb-28-22Initiated H.C. Wainwright Neutral
Dec-07-21Resumed Cowen Outperform
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
Oct-03-23 04:30PM
Sep-27-23 09:24PM
Sep-25-23 09:55AM
Sep-20-23 07:29AM
01:09PM Loading…
Sep-15-23 01:09PM
Sep-14-23 11:02PM
Sep-08-23 12:00PM
Sep-07-23 04:02PM
Sep-06-23 04:30PM
Sep-05-23 04:30PM
Aug-08-23 04:03PM
04:30PM Loading…
Aug-02-23 04:30PM
Aug-01-23 08:00AM
Jul-05-23 07:30AM
Jun-14-23 01:00PM
Jun-02-23 04:30PM
May-30-23 04:30PM
May-19-23 06:29AM
May-11-23 08:43AM
May-09-23 04:01PM
May-08-23 07:06AM
May-02-23 04:30PM
Apr-13-23 04:30PM
Apr-04-23 04:30PM
Mar-09-23 04:00PM
Mar-02-23 05:00PM
04:05PM Loading…
Feb-21-23 04:30PM
Feb-02-23 06:00PM
Jan-04-23 04:30PM
Jan-03-23 07:00AM
Jan-02-23 08:23AM
Dec-07-22 03:37PM
Dec-02-22 04:30PM
Nov-21-22 09:16AM
Nov-08-22 04:30PM
Nov-02-22 04:30PM
Nov-01-22 08:00AM
Oct-26-22 08:01AM
Oct-12-22 07:01AM
Oct-04-22 04:29PM
Sep-06-22 04:30PM
Sep-01-22 05:01PM
Aug-09-22 04:35PM
Aug-04-22 04:30PM
Aug-03-22 04:30PM
Jul-26-22 07:32AM
Jul-22-22 06:49AM
Jul-21-22 07:30AM
Jul-07-22 10:40AM
Jul-05-22 04:30PM
Jun-09-22 07:35AM
Jun-02-22 04:30PM
May-24-22 04:30PM
May-09-22 04:30PM
May-03-22 04:30PM
Apr-18-22 04:30PM
Apr-04-22 07:30AM
Mar-08-22 04:35PM
Feb-28-22 04:30PM
Feb-22-22 07:30AM
Feb-16-22 10:06AM
Feb-03-22 05:00PM
Jan-31-22 07:30AM
Jan-04-22 07:30AM
Dec-16-21 12:38PM
Dec-01-21 04:09PM
Nov-30-21 11:02AM
Nov-29-21 04:27PM
Nov-22-21 07:30AM
Nov-19-21 12:00PM
Nov-10-21 04:05PM
Nov-09-21 07:30AM
Oct-18-21 11:01AM
Oct-13-21 11:43AM
Sep-30-21 05:00PM
Sep-09-21 07:30AM
Aug-30-21 04:05PM
Aug-18-21 10:46AM
Aug-10-21 04:05PM
Jul-28-21 04:05PM
May-18-21 04:05PM
May-11-21 04:05PM
Apr-07-21 07:30AM
Apr-06-21 07:30AM
Mar-17-21 04:05PM
Mar-10-21 04:45PM
Feb-23-21 07:00AM
Feb-19-21 04:59AM
Dec-31-20 03:42PM
Dec-17-20 07:00AM
Dec-07-20 07:39AM
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harmon CyrusDirectorSep 29Sale12.4125,000310,250973,714Oct 03 05:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSep 19Sale12.6720,000253,400572,011Sep 21 05:00 PM
BVF PARTNERS L P/ILDirectorSep 12Buy9.841,505,93214,818,3714,688,954Sep 14 04:25 PM
Harmon CyrusDirectorSep 05Sale11.6210,000116,200998,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 31Sale9.3615,000140,4001,008,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 16Sale10.1415,000152,1001,023,714Aug 17 05:00 PM
Harmon CyrusDirectorJun 08Sale6.3010,00063,0001,038,714Jun 09 05:30 PM
Harmon CyrusDirectorJun 06Sale6.295,00031,4751,048,714Jun 07 09:30 PM
Harmon CyrusDirectorJun 05Sale6.045,00030,2251,053,714Jun 07 09:30 PM